

1        **An Oxford Nanopore-based Characterisation of Sputum Microbiota Dysbiosis in**  
2        **Patients with Tuberculosis: from baseline to 7 days after Antibiotic Treatment**

3        John Osei Sekyere<sup>#</sup>, Nontuthuko E. Maningi, Siphwiwe Ruthy Matukane, Nontombi M.  
4    Mbelle, Petrus Bernard Fourie<sup>#</sup>

5        Department of Medical Microbiology, School of Medicine, Faculty of Health Sciences,  
6    University of Pretoria, South Africa.

7        #Address correspondence to Dr. John Osei Sekyere ([jod14139@gmail.com](mailto:jod14139@gmail.com)) or Professor P  
8        Bernard Fourie ([bernard.fourie@up.ac.za](mailto:bernard.fourie@up.ac.za)), Department of Medical Microbiology, University  
9    of Pretoria.

10

11      **Running head:** Antibiotic-based dysbiosis in TB patients

12      **Tweet:** “*Oxford Nanopore’s MinION sequencer can be a useful tool for diagnosing*  
13      *tuberculosis and other polymicrobial infections, identifying resistance genes and mobile*  
14      *genetic elements, and monitoring treatment and its effect on the host’s microbiome*”

15      **Author summary**

16      Tuberculosis (TB), one of the major killers of mankind, continually remains elusive as  
17      challenges with early diagnosis and treatment monitoring remain. Herein, we use a single  
18      portable sequencer from Oxford Nanopore, the minION, to diagnose TB and monitor its  
19      treatment with antibiotics using routine sputum samples. In addition, the presence of other  
20      pathogens, important commensals, antibiotic resistance genes, mobile genetic elements, and  
21      the effect of the antibiotic treatment on the sputum microbiota were determined from the  
22      same data. This makes the minION an important tool that can be used in clinical laboratories  
23      to obtain data that can inform live-saving decisions.

24 **Abstract**

25 **Background.** Diagnostics for tuberculosis (TB) and treatment monitoring remains a  
26 challenge, particularly in less-resourced laboratories. Further, the comprehensive sputum  
27 microbiota of TB patients during treatment are less described, particularly using long-read  
28 sequencers.

29 **Methods.** DNA from sputum samples collected from newly-diagnosed TB patients were  
30 sequenced with Oxford Nanopore's MinION. MG-RAST and R packages (Phyloseq,  
31 Microbiome) were used to determine the OTUs abundances,  $\alpha/\beta$  diversities, functional  
32 components, OTUs networks and ordination plots. Statistical significance of the generated  
33 data was determined using GraphPad.

34 **Results & conclusion.** Antibiotics reduced the abundance and functional subsystems of each  
35 samples' microbiota from baseline until day 7, when persistent, tolerant, and resistant  
36 microbiota, including fungi, grew back again. Variations in microbiota abundance and  
37 diversity were patient-specific. Closer microbiome network relationships observed in baseline  
38 samples reduced until day 7, when it became closer again. Bacterial microbiota networks and  
39 spatial ordination relationships were closer than that of other kingdoms. Actinobacteria  
40 phylum and Mycobacterium were more affected by antibiotics than other phyla and genera.  
41 Parasites, viruses, and fungi were less affected by antibiotics than bacteria in a descending  
42 order. Resistance genes/mechanisms to important antibiotics, plasmids, transposons, insertion  
43 sequences, integrative conjugative elements were identified in few samples.

44 MinION can be adopted clinically to monitor treatment and consequent dysbiosis, and  
45 identify both known and unknown pathogens and resistance genes to inform tailored  
46 treatment choices, specifically in TB.

47 **Keywords:** *Mycobacterium tuberculosis*; *microbome*; *treatment monitoring*; *diagnostics*;  
48 *metagenomics*.

## 49 **Introduction**

50 Tuberculosis (TB), shall we ever overcome it? This question has been ringing through the  
51 annals of history over several millennia among diverse cultures and regions as the ‘white  
52 plague’ continues to devastate humanity and elude total eradication; a conundrum that still  
53 baffles clinicians, particularly with the current advancements in modern medicine<sup>1-3</sup>.  
54 Tuberculosis remains the deadliest infectious disease caused by a single aetiological agent,  
55 *Mycobacterium tuberculosis* (MTB), which is an acid-fast bacilli and intracellular bacterial  
56 pathogen<sup>4-6</sup>. In 2019, 1.4 million people died from TB alone, including 208,000 who had  
57 HIV<sup>7</sup>. Whereas TB is treatable and curable with first-line drugs such as isoniazid (INH) and  
58 rifampin (RFP), multidrug-resistant TB (MDR-TB), which was found in 206 030 people  
59 globally in 2019, requires more toxic, expensive, and scarce second-line chemotherapeutic  
60 agents that are taken for two years<sup>5,7-9</sup>.  
61 Until recently, the lung microbiome was believed to be sterile. However, the advent of non-  
62 culture-based techniques has shown the presence of a stable microbiota in the lung<sup>6,10</sup>.  
63 Furthermore, increasing evidence suggests that the intestinal microbiome modulates the lung  
64 microbiome through immune system regulation, development and inducement<sup>11,12</sup>. Several  
65 studies have shown that TB antibiotics, although taken orally, affect the upper and lower  
66 airways microbiome<sup>4,6</sup>. This interaction between the gut-lung microbiome is mediated  
67 through the immune system, and is being harnessed to enhance the treatment of asthma,  
68 cystic fibrosis, chronic obstructive pulmonary diseases (COPD) through the administration of  
69 probiotics and prebiotics that confers a microbiota than regulates inflammatory responses in  
70 the lungs<sup>11-14</sup>. Specifically, *Lactobacillus plantarum*, a gut commensal, has been shown to  
71 reverse TB progression and pathologies in the lungs<sup>6</sup>. A few studies have proposed the

72 presence and possible adoption of signature microbiota species that are indicative of the  
73 presence of TB and can be used for detection and treatment monitoring <sup>15,16</sup>. However, this is  
74 yet to be established and adopted as some studies also suggest otherwise <sup>17</sup>.

75 The emergence and declining costs of whole-genome sequencing (WGS), with its varied  
76 applications in metagenomics <sup>18,19</sup>, and meta-transcriptomics <sup>20,21</sup>, are revolutionizing  
77 molecular biology research. Particularly, metagenomics promises a faster and more efficient  
78 detection of MTB infections and mixed infections, resistance profile, lineage of MTB strains,  
79 and epidemiological spread of TB outbreaks for efficient management and control of TB  
80 <sup>1,18,22,23</sup>. Thus, several propositions have been made to adopt WGS as a diagnostic tool for  
81 MTB in the clinical microbiology laboratory <sup>1,18,22,23</sup>. Of the 14 studies describing the  
82 microbiome of sputum samples from TB patients at the time of writing, none have so far used  
83 long-read sequencers such as Oxford Nanopore Technology's (ONT) MinION. All the  
84 reported studies either used Roche's 454/GS FLX-Titanium (pyrosequencing) or Illumina's  
85 Miseq/Hiseq to sequence the 16s rRNA <sup>24-28</sup>. Only one study has so far undertaken a shot-gun  
86 metagenomic analysis of bronchoalveolar lavage (BAL) samples of TB patients <sup>29</sup>.

87 Hence, this study is the first to use a long-read sequencer to describe the sputum microbiota  
88 of TB patients. We show that the MinION can be adopted in clinical laboratories as a  
89 diagnostic tool to detect pathogens, monitor treatment outcomes and microbiota changes, and  
90 identify resistance genes/mutations and mobile genetic elements (MGEs).

## 91 **Methods**

### 92 *Study design and sampling*

93 This was a prospective study carried out at a TB clinic based at Stanza Bopape, Pretoria,  
94 South Africa, in 2019. Twenty-one patients were recruited between June and August 2019 for  
95 the study. Participants were persons newly confirmed to have pulmonary TB (using

96 GeneXpert), but who were not yet on treatment. Sputum samples were collected from each  
97 participant at four different timepoints: baseline (day 0), day 1, day 2, and day 7. Baseline  
98 samples were collected prior to the beginning of antibiotic therapy whilst days 1, 2, and 7  
99 samples were collected one day, two days, and seven days after starting antibiotic treatment.  
100 As the patients were all newly diagnosed with TB, they were placed on fixed-dose  
101 combination (FDC) treatment involving first-line anti-TB drugs i.e., rifampicin, isoniazid,  
102 pyrazinamide, and ethambutol. Demographic data of the patients viz., age and sex, were also  
103 collected.

#### 104 *Sample treatment and sequencing*

105 The collected sputum samples were transferred into the mycobacteriology laboratory  
106 (University of Pretoria) in wrapped sputum containers and stored at -4 ° Celsius. The samples  
107 were divided into two and one part was immediately dissolved in PrimeStore® Molecular  
108 Transport Medium (MTM) for long-term storage. Another part was immediately used for  
109 DNA extraction using the Ultra-Deep Microbiome Prep kit (Molzym GmbH & Co. KG,  
110 Bremen, Germany), which depletes host DNA and enriches microbial DNA. The extracted  
111 DNA was analysed using a NanoDrop spectrophotometer and gel electrophoresis to  
112 determine their quality, quantity, and length.

113 ONT's Rapid Barcoding Sequencing kit, SQK-RBK004, was used to prepare the DNA  
114 libraries for MinIon sequencing, following the recommended protocol. Briefly, the DNA  
115 (~400ng) of 12 samples were transferred into 12 DNA LoBind tube and adjusted with  
116 nuclease-free water up to 7.5µL; 2.5µL of Fragmentation Mix RB01-12 was added to make  
117 up to 10µL. The tubes were flicked gently to mix the contents and incubated at 30 °C (for 1  
118 min) and at 80 °C (for 1 min) to simultaneously fragment and tag the DNA with unique  
119 barcodes. The barcoded samples were then pooled into one 2 mL Eppendorf tubes and  
120 washed with AMPure XP beads and a magnetic rack to purify the barcoded DNA.

121 Subsequently, 1  $\mu\text{L}$  of RAP was added to 10  $\mu\text{L}$  of pooled barcoded DNA, incubated for 5  
122 minutes, and mixed with 34  $\mu\text{L}$  of sequencing buffer, 25.5  $\mu\text{L}$  of loading beads, and 4.5  $\mu\text{L}$   
123 of nuclease-free water prior to loading into an already primed MinION FLO-MIN 106D  
124 R9/R10 flow cell. The sequencing was done for 12 hours per batch of 12 pooled barcoded  
125 samples. This was repeated for the other samples in batches of 12.

### 126 *Bioinformatics and statistical analysis*

127 The generated Fast5 sequences reads were de-barcoded into individual sample DNA and  
128 converted into FastQ files using the MinKNOW and EPI2ME applications provided by ONT.  
129 Sequence reads with coverage below 10X were deleted/removed. Initial taxonomy and  
130 resistance determinants in each sample were provided by EPI2ME. The FastQ files were  
131 assembled into FastA files using Canu 2.1 on Ubuntu 18.04LTS using default parameters.  
132 The assembled FastA files were uploaded to ResFinder  
133 4.1(<https://cge.cbs.dtu.dk/services/ResFinder/>) /ResFinderFG 1.0  
134 (<https://cge.cbs.dtu.dk/services/ResFinderFG/>), PlasmidFinder 2.1  
135 (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>), and Mobile Element Finder  
136 (<https://cge.cbs.dtu.dk/services/MobileElementFinder/>) databases to determine resistance  
137 mechanisms, plasmids, and mobile genetic elements respectively in the assembled reads.  
138 The FastQ files were uploaded to MG-RAST<sup>30</sup>, from where the distribution of functional  
139 categories for COGs, KOs, NOGs, and Subsystems, alpha diversities, rarefaction curves,  
140 taxonomies, sequence length histogram, and sequence GC contents per sample were obtained.  
141 Operational taxonomic units (OUT), metadata, and taxonomy tables were built from the MG-  
142 RAST data and used for downstream analyses in R using Phyloseq<sup>31</sup> and Microbiome  
143 (<http://microbiome.github.com/microbiome>) packages. The Chao1 and Shannon indices  
144 (alpha diversity), abundance of each taxonomy per sample, non-metric multidimensional  
145 scaling (NMDS), and ordination of the various taxa per sample were obtained using

146 Microbiome, Phyloseq<sup>31</sup>, tidyr (<https://tidyr.tidyverse.org/>), dplyr ([https://cran.r-](https://cran.r-project.org/web/packages/dplyr/vignettes/dplyr.html)  
147 [project.org/web/packages/dplyr/vignettes/dplyr.html](https://cran.r-project.org/web/packages/dplyr/vignettes/dplyr.html)), and ggplot2  
148 (<https://ggplot2.tidyverse.org/>) packages in R.

149 Beta diversities were manually calculated using the formula  $\beta = (S1-c) + (S2-c)$ , where  $\beta$  is  
150 the beta diversity, S1 is the total number of species in the first environment, S2 is the total  
151 number of species in the second environment, and c is the number of species that the two  
152 environments have in common.  $\beta$  diversities between samples from the same and different  
153 patients were thus calculated.

154 The significance of each taxa abundance across samples, of alpha and beta diversities per  
155 sample and between samples, and of archaea, bacterial phyla, viral, fungal, and parasitic taxa  
156 across samples were determined using Wilcoxon's signed rank test, one sample t test, and  
157 one-/two-way ANOVA. Descriptive statistics, row means, and variance were also determined  
158 using column statistics. All statistical analysis were carried out using GraphPad Prism 9.1.0  
159 (221); p-values of <0.05 were defined as significant.

#### 160 ***Ethical clearance***

161 Ethical approval was provided by the Human Research Ethics Committee, Faculty of Health  
162 Sciences, University of Pretoria, South Africa. All protocols and consent forms were  
163 executed according to the agreed ethical approval terms and conditions. All clinical samples  
164 were obtained directly from patients, who agreed to our using their specimens for this  
165 research. The guidelines stated by the Declaration of Helsinki for involving human  
166 participants were followed in the study.

#### 167 ***Data availability***

168 This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank

169 under the Bioproject accession PRJNA673633 and Biosample accessions JAFMQ-  
170 JAFJNR000000000. The versions described in this paper is version JAFMQ-JAFJNR  
171 010000000.

## 172 **Results**

### 173 *Demographics and Sequencing reads*

174 The study recruited 21 patients, aged between 23 and 55 years with an average age of 37.41  
175 years and median age of 38 years. Six of the patients were females whilst 15 were males,  
176 with the females and males having a respective mean age of 30.60 and 40.25 years (Figure  
177 1A; Dataset 1). Only 11 out of the 21 patients provided sputum samples within the time  
178 frame of the study. Complete sputum samples i.e., sputum samples collected at baseline, day  
179 1, day 2, and day 7, were obtained from seven patients whilst three patients provided samples  
180 at baseline, day 1, and day 2. One patient provided only baseline and day 7 sputum samples  
181 (Fig. 1C). Only nine of the 11 sequenced reads qualified for inclusion in downstream analysis  
182 owing to their higher coverage ( $>10X$ ) (Fig. 1D; Dataset 1). The sequence lengths ranged  
183 from  $1529\pm 738\text{bp}$  to  $3396\pm 1305\text{bp}$  whilst the mean GC contents ranged from  $40\pm 5\%$  to  
184  $50\pm 10\%$  (Dataset 1).

### 185 *Taxonomy, abundance, & diversities*

186 A of total 40 phyla comprising 347 genera, belonging to Bacteria ( $n=258$ ), Fungi ( $n= 50$ ),  
187 Eukaryota ( $n=11$ ), Animalia/Metazoa ( $n=8$ ), Archaea ( $n=4$ ), Plantae ( $n=3$ ), Protista ( $n=2$ ),  
188 and Chromista ( $n=1$ ) were identified in the sputum samples (Dataset 2); variations in  
189 abundance for these kingdoms across samples were statistically significant. A core  
190 microbiota of 56 genera, which were present in at least 70% of all samples, was identified.  
191 The count of each genus for all the samples, categorised into abundances above 1000,  
192 between 100 and 1000, between 10 and 100, and below 10, showed that most genera fell



193 below a total abundance of 10 whilst a few fell above a total abundance of 1000.  
194 Streptococcus (p-value: 0.0078; <0.0001), Actinomyces (p-value: 0.1245; <0.0001),  
195 Mycobacterium (p-value: 0.1149; <0.0001), Granulicatella (p-value: 0.0432; <0.0001),  
196 Atopobium (p-value: 0.0078|<0.0001), Meyerozyma (p-value: 0.318;|<0.0313), Rothia (p-  
197 value: 0.1853|<0.0001), Catonella (p-value: 0.0884; <0.0001), Penicillium (p-value: 0.3076;  
198 <0.0078), Lactobacillus (p-value: 0.0272|<0.0001), Gemella (p-value: 0.0902; <0.0001),  
199 Veillonella (p-value: 0.2216; <0.0001), Candida (p-value: 0.0612; <0.0001), Pseudomonas  
200 (p-value: 0.0147; <0.0001), and Propionibacterium (p-value: 0.1174; <0.0001) were among  
201 the most dominant genera, with OTU abundance above 1000, in all samples (Figure S1).

202 The abundance of each OTU differed per sample, with baseline samples (D0) from patient  
203 104 having the highest abundance. Notably, baseline samples from patients 104, 105, 107,  
204 108, and 112 were higher than subsequent samples from days 1, 2, and 7 except in samples  
205 from patients 109 and 117 where baseline samples had lower genera abundance than samples  
206 from subsequent days (Fig. 2A; p-value: 0.005; <0.0001). Interestingly, samples from day 7  
207 had higher OTU abundance than those from days 1 and 2, except in patients 107 (Fig. 2A).  
208 The absolute counts of the genera (diversity) per sample showed unique characteristics per  
209 patient. For instance, there were more diverse kinds of genera in baseline samples than  
210 samples from days 1 and 2 in patients 104 and 108, as well as than day 1 samples in patients  
211 105, 107, 112, and 117. However, baseline samples were lower than samples from  
212 subsequent days in patient 109 (Fig. 2B). The highest genera count was in sample 108D0 (p-  
213 value: <0.0001).

#### 214 *Alpha and Beta diversities*

215 The variation in alpha diversity (provided by MG-RAST) in samples from each patient was  
216 not consistent across patients; each patient had a unique variation in alpha diversity (p-value:

217 <0.0001). Specifically, there were variations in alpha diversities between samples from the  
218 same patient, but in patients 105, 108, 109, 111, 112, and 117, there was an increase in alpha  
219 diversities from either baseline or day 1 up to days 2 or 7 (Fig. 2C). The alpha-diversities  
220 were different from the absolute count of genera types per samples, which tended to follow a  
221 u-shaped pattern per patient (Figure 2B-C).

222 The Chao1 and Shannon alpha diversities (provided by Phyloseq) of each sample were not  
223 the same and also differed within patients (Figure S1). Whereas the alpha diversities between  
224 samples of the same patient were very close in the Chao1 index, they varied widely from  
225 each other in the Shannon index. Using the Chao1 index, there was a general reduction in  
226 alpha diversity of samples from baseline to days 1 and 2, except in patient 109. However,  
227 there was a rise in alpha diversity of the samples at day 7 after a drop in days 1 and 2. In  
228 patient 109, there was a rise in alpha diversity from baseline to day 1, after which the alpha  
229 diversity dropped from day 2 to day 7. Furthermore, in patient 117, the baseline diversity was  
230 higher than that on day 7. Patient 107 had a higher alpha diversity on day 2 than days 0  
231 (baseline) and 1.

232 A similar pattern was observed in the Chao1 alpha diversity of bacterial genera in the  
233 samples. Generally, there was a drop in Chao1 alpha-diversity from baseline to days 1 and 2  
234 samples whilst day 7 samples had higher alpha-diversity than baseline, day 1, and day 2  
235 samples, suggesting a growing of drug-resistant/tolerant species during the 7<sup>th</sup> day. The  
236 exception was observed in patient 117 where day 7 samples had lower alpha-diversity than  
237 baseline samples. Similarly, patient 107 had days 1 and 2 samples having higher alpha-  
238 diversities than baseline samples (Figure S2). However, the Chao1 and Shannon alpha-  
239 diversities of fungi, parasites/protozoa, and virus in the various samples showed relatively  
240 minor, little or no differences at all (Fig. S2.vii-ix).

241 A comparison of both Chao1 and Shannon alpha diversities of baseline and days 1, 2, and 7  
242 samples from all patients are also shown in Fig. S2(iii-vi). For samples collected at any given  
243 timepoint (baseline, days 1, 2, and 7), there were variations between patients, highlighting  
244 personal microbiome diversity.

245 Figure 2B shows the  $\beta$ -diversities (differences in genera diversities) between different  
246 samples from the same patient (p-values:  $< 0.0001$ ). The chart shows that there were  
247 variations in genera diversity between samples from different time points i.e., baseline (S1),  
248 day 1 (S2), day 2 (S3), and day 7 (S4), in all patients. Particularly,  $\beta$ -diversities of samples  
249 from patients 108 and 107 were very high, followed by that of patients 111, 109, 112, 117,  
250 105, and 104. In patient 107, the  $\beta$ -diversity between days 0 and 1 (S1|S2) samples were very  
251 low compared to that of days 0 and 2 (S1|S3), days 0 and 7 (S1|S4), days 1 and 2 (S2|S3), and  
252 days 2 and 7 (S3|S4). However, in patient 108, inter-sample  $\beta$ -diversity was highest between  
253 days 0/baseline and 7 (S1|S4), days 0 and 1 (S1|S2), and days 0 and 2 (S1|S3). The inter-  
254 sample  $\beta$ -diversities variation per patient were not as relatively vast as that of patients 107  
255 and 108.

256 The inter-patient samples  $\beta$ -diversities showed that the largest variations occurred in baseline  
257 samples from the different patients (blue bars in Fig. 2C). Specifically,  $\beta$ -diversity variations  
258 between samples of patient 108 and other patients were distinctly wide (p-value:  $<0.0001$ ).  
259 Also notable were variations between days 2 (S3|S3) and 7 (S4|S4) samples' genera (Fig.  
260 2C).

### 261 *Kingdom-specific abundances*

262 Analysis of the proportion of each kingdom in each collected sputum microbiota is presented  
263 in Figures 3A and S3. There were five main kingdoms viz. archaea, bacteria, virus, fungi, and  
264 parasites (protista), and minor kingdoms such as eukaryota, and animalia (metazoa). Bacteria

265 was the most dominant kingdom across all samples (p-value: <0.0086; < 0.0001) except in  
266 107D2, 109D1, and 109D2, where fungi was most dominant (p-value: 0.2068; <0.0001).  
267 Parasites were also found in substantial proportions in 104D1, 105D2, 107D7, 108D1,  
268 108D2, 109D1, 109D2, and 112D2 (p-value: <0.0047; <0.0001), but viruses (p-value:  
269 0.0332; <0.0001) and archaea (p-value: 0.3277; >0.999) were very minor in abundance in all  
270 the samples (Fig. 3A & S3). A detailed breakdown of each phylum, class, order, family, and  
271 genus in each sample across all time points and in only baseline, day 1, 2, and 7 samples are  
272 shown in Figure S3.

273 Among Bacteria, the most common phyla were Firmicutes (p-value: 0.0069; <0.0001),  
274 Actinobacteria (p: 0.0348; <0.0001), Proteobacteria (p: 0.0066; <0.0001), and Bacteroidetes  
275 (p: 0.0037; <0.0001) (Fig. 4). In almost all the samples, the bacterial phylum Firmicutes was  
276 the most dominant, except in 105D2, 107D2, 108D1, and 112D2 where it was almost absent.  
277 Actinobacteria was the next dominant phylum, with Proteobacteria, Bacteroidetes and the  
278 other phyla occupying a relatively small portion of the microbiota. A reduction in bacterial  
279 phyla abundance was seen after the baseline until day 7, when a rise in abundance was  
280 observed again in all the samples (Fig. 3B). The most abundant genera were Streptococcus,  
281 followed by Mycobacteria (sea-blue bar), Actinomyces (orange bar), Pseudomonas (purple  
282 bar), and Rothia (mauve). Bacilli, Alphaproteobacteria, Actinobacteria,  
283 Epsilonproteobacteria, and Gammaproteobacteria were common bacterial classes whilst  
284 Clostridiales, Actinomycetales, Lactobacillales, Burkholderiales, and Micrococcales were the  
285 commonest bacterial orders that changed in abundance over the different time points (Fig.  
286 S4).

287 A u-shaped pattern was observed among bacterial genera in the various phyla (Fig. 4): the  
288 abundance of the genera reduced from baseline and rose gradually from day 2 to day 7.  
289 Genera diversity were not consistent from baseline to day 7; it was patient specific (Fig. 4).

290 This decline in abundance among the genera is more clearly observed in Figure 5; but  
291 *Mycobacterium* continued declining after the baseline value ( $p: <0.0001$ ). Detailed  
292 breakdown of all bacterial taxonomic ranks and OTUs per sample collection time are  
293 provided in Fig. S4.

294 Archaea was only present in 108D0 (baseline sample) and included only four genera:  
295 *Ferroglobus*, *Methanocaldococcus*, *Methanococcus*, and *Methanosaeta* (Fig. 6A); none of the  
296 abundance variations of these genera were statistically significant. Fifteen genera were  
297 identified in all samples as parasites, with *Codonosigidae* ( $p: 0.0612; <0.0001$ ) and  
298 *Schistosoma* ( $p: 0.0014; <0.0001$ ) being the most abundant and common. Notably, the  
299 variations in abundance in parasitic genera were not consistent between baseline and days 1,  
300 2, and 7; most of these genera had non-significant variations in abundance (Dataset 3). In  
301 patient 104, there was a reduction in abundance in parasitic genera from baseline to day 7, but  
302 this was not the case in other patients. In 105, there was a rise in parasitic genera on day 2  
303 and a fall on day 7. In 107, there was a sharp fall in parasitic genera abundance on day 1, a  
304 gradual rise on day 2, and a sharp rise on day 7, which was higher than that of the baseline.  
305 Similarly, a sharp rise in parasitic genera was observed on days 1 and 7 in 109. However, a  
306 gradual rise in parasitic genera was observed in 108 up to day 2, when it dropped  
307 significantly on day 7 (Figure 6B).

308 Under parasites were kingdoms such as Animalia, Chromista, Eukaryota, Metazoa, and  
309 Protista, which varied across the different time points after commencement of antimicrobial  
310 chemotherapy. Further breakdown of the various taxonomic ranks under these kingdoms per  
311 sample is shown in Figure S5.

312 Unlike parasites, fungi were not found in all samples although there were 51 fungal genera,  
313 making them the second most common kingdom after bacteria. Specifically, fungi were

314 absent from patient 104, and in samples 105D0, 107D0, 107D1,108D1, 108D2, 109D7 and  
315 117D7. *Saccharomyces* (p: 0.0821; 0.0078) was a common fungi genus in the samples,  
316 particularly in 105D2, 105D7 and 106D7. Other common fungi genera were *Penicillium* (p:  
317 0.3076; 0.0078), *Meyerozyma* (p: 0.318; 0.0313), and *Debaryomyces* (p: 0.163; 0.0625).  
318 Variations in abundance and diversity of fungal genera were observed across different time  
319 points in some samples, but none of the genera had significant variations in abundance across  
320 the samples (Dataset 3). Particularly, there was a sharp rise in *Saccharomyces* in 105D2 and  
321 105D7, albeit there was none in the baseline, suggesting that it increased in the microbiota  
322 after antibiotics were introduced. There was a drop in abundance of *Penicillium* from 107D2  
323 to 107D7 whilst several fungal genera such as *Meyerozyma* and *Saccharomyces* emerged,  
324 increasing the diversity. Changes in fungal abundance and diversity were also observed in  
325 patients 108, 109, and 111 (Fig. 6C). Detailed breakdown of fungal genera per sample  
326 according to taxonomic rank is shown in Figure S6.

327 Viruses from Siphoviridae were the commonest and most abundant in all samples,  
328 particularly baseline samples from patients 104, 107, 108, 112, and 117 as well as day 7  
329 samples from patients 105, 106, 107, 108, 109, and 117. Notably, viruses, including  
330 Siphoviridae, were almost absent in days 1 and 2 samples, except in 105D2, 107D2, and  
331 111D1. Myoviridae, Podoviridae, and T4-like viruses were also present in mainly baseline  
332 samples and to a lesser extent, day 7 samples, from patients 105, 106, 107, 108, 112, and 117;  
333 107D2 was the only day 2 sample with these viruses (Fig. 6D). None of the viral OTUs had  
334 significant variations in abundance across the samples (Dataset 3). Detailed viral OTUs per  
335 taxonomic rank in each sample is detailed in Figure S7.

### 336 ***Functional subsystems components***

337 A functional subsystem component analyses (generated by MG-RAST) showed the  
338 proportional changes in key cellular processes and components in each sputum sample from

339 baseline through days 1, 2, to 7. Instructively, the functional component of each sample was  
340 strongly/significantly associated with its abundance in that sample (Dataset 3). The major  
341 functional subsystems in all the microbiota samples were clustering-based subsystems,  
342 carbohydrates, protein metabolism, DNA and RNA metabolism, cofactors, vitamins,  
343 prosthetic groups & pigments, and cell wall and capsules. Baseline and to some extent, day 7,  
344 samples had the most abundant and diverse functional subsystems compared to those of days  
345 1 and days 2. The functional components of the sputum microbiota decreased from baseline  
346 to day 2 and increased gradually on day 7. An exception was observed in samples 109 and  
347 117, in which day 7 samples had higher abundance and diversity of functional components  
348 than the baseline samples (Fig. 7).

#### 349 *Network and ordination analysis*

350 The spatial relationship and networking between the microbiota in the sputum samples  
351 collected at different time points showed a reduction in the microbial networks from baseline  
352 to day 7, with a thickening of the networks on day 7. The closer connection seen in the  
353 networks shows the close interactions between the microbiota. Compared to bacteria,  
354 network analyses for parasites were relatively less busy and interconnected. The changing  
355 diversity of the phyla or classes (OTUs) in the collected samples at different time points is  
356 also seen in the widening network distances and reducing interconnections between the  
357 various classes (OTUs) (Figures 8, S9 and S10).

358 In the nonmetric multidimensional scaling (NMDR) ordination plots, a closer spatial  
359 relationship existed between bacteria than fungi, virus, and parasite OTUs.

360 Gammaproteobacteria, Bacilli, Erysipelotrichia, Clostridia, and Actinomycetes, filled distinct  
361 spaces distant from other classes that clustered together. The greatest change in ordination  
362 was seen in bacterial classes. The day 1 ordination was closer to each other than the baseline

363 plots. Virtually no change was observed between the classes of other kingdoms in day 1 and  
364 baseline (Fig. S10).

### 365 ***Resistance genes and mobile genetic elements***

366 Resistance determinants to tetracyclines (*tet*), aminoglycosides (*aph*, *aac(2')*, *aac(3')*),  
367 macrolides (*erm*, *mef*, *msr*), quinolones (*qnrD*, unknown *gyrAB* mutations), isoniazid (*katG*:  
368 N138T, K143T, Y155S), capreomycin (*tlyA*: A67E), para-aminosalicylic acid (*ribD*: G8R),  
369 rifampicin (*rpoC*: F6V, F7A, L10H, W23R, S24\*), ethionamide (*ethR*: R19?, D96G, R164?,  
370 T165?), pyrazinamide (*pncA* mutations), and ethambutol (*embR* mutations) were found in  
371 only eight sputum samples. Mobile genetic elements such as plasmids (ColRNAI, repUS38,  
372 repUS43, rep5e, repUS34), transposons (Tn253), integrative conjugative element (ICE) and  
373 insertion sequences (IS30, ISL, IS3, IS4, IS1182) were also found either alone or in  
374 association with antibiotic resistance determinants in 13 samples (Dataset 2).

### 375 **Discussion**

376 In this work, we show how ONT's MinION can be used to monitor the treatment outcome of  
377 TB, detect MTB and other associated bacterial, fungal, parasitic, and viral pathogens, identify  
378 antimicrobial resistance determinants and mobile genetic elements, and monitor microbiota  
379 changes (dysbiosis) during antimicrobial chemotherapy using sputum. Hence, the importance  
380 of using this portable technology in clinical settings to diagnose infections, inform  
381 antimicrobial treatment choices, monitor the effects of antimicrobials on the gut, oral, upper  
382 airways and lungs microbiota, despite its inherent challenges, cannot be gainsaid.

383 Using sputum samples from patients freshly diagnosed with tuberculosis, it was observed that  
384 the microbiota of the sputum samples collected prior to the initiation of antibiotic therapy  
385 (baseline samples) comprised of more diverse and abundant microbial genera (OTUs) than  
386 that observed in days 1, 2, and 7 (Fig. 2-6). Albeit there were a few exceptions to this pattern,



387 the higher abundance and diversity of microbiota in the sputum of untreated patients testify to  
388 the effect of antitubercular drugs on the sputum microbiota. Thus, although the antibiotics are  
389 taken orally, they become bioavailable in the sputum through the blood.

390 It is interesting to note that the microbial abundance and diversity began to increase on day 7  
391 after onset of treatment, suggesting the regrowth of persistent, tolerant or resistant microbiota  
392 after day 7 of treatment. However, this was not observed with *Mycobacterium*, which  
393 continued declining even after day 7. This is expected because the antibiotics given to the  
394 patients, i.e. isoniazid, rifampicin, pyrazinamide, and ethambutol, are narrow-spectrum  
395 antibiotics targeting *Mycobacterium*. Notwithstanding the narrow spectrum nature of these  
396 antibiotics, they did affect the abundance and diversity of the microbiota, including bacteria,  
397 fungi, parasites, and viruses, although their effect on non-bacterial microbiota were relatively  
398 limited (Figure 2-5). Recently, Kateete et al. (2021) observed a significant mean reduction in  
399 the microbiota biomass in the sputum of TB patients 2 months after onset of treatment.  
400 Further, Sala et al. (2020) found non-significant changes in microbiota diversity in sputum of  
401 TB patients up to 7 months. As the authors did not collect and analyse samples at day 7, a  
402 comparative analysis cannot be made<sup>17,32</sup>.

403 The change in microbial abundance and diversity after antibiotic treatment reflected in the  
404 functional components subsystems dynamics, ordination plots and network analyses (Fig. 7-  
405 8; S8-S10). Particularly, the abundance of each functional subsystem in samples collected  
406 from the same patient from baseline to day 7 also dropped on days 1 and 2, and rose on day 7  
407 whilst the network relationship between the microbiota reduced from baseline samples until  
408 they increased on day 7. This is expected, as the biocidal action of the antibiotics on the  
409 microbiota will definitely reduce the number of microbes and their functions in the upper air  
410 ways (Fig. 7). Hence, any beneficial effect of the microbial activity in the upper airways,  
411 including the production of metabolites important to the host, will be negatively affected.

412 Further, the regrowth of the microbiota and the increase in their metabolic functions from day  
413 7 suggests the evolution and emergence of tolerance, persistence, and resistance, which  
414 numbs the effects of the antibiotics on these microbes. Further, the reducing microbial  
415 abundance also reduced the spatial interrelationship between the microbes until day 7, when  
416 they grew back and strengthened the networks between them again (Fig. S9-S10). This shows  
417 the short-term effect of antibiotics in generating resistance and demonstrates why it is  
418 inadvisable to use antibiotics beyond a week for normal infections.

419 The functional components and subsystems of the microbiota (Fig. 7) gives a comprehensive  
420 overview of the cellular activities (metabolic pathways), components, and metabolites  
421 produced by the microbiota. Notably, most of the samples were dominated by clustering-  
422 based subsystems (contain functions such as proteosomes, ribosomes and recombination-  
423 related clusters), carbohydrates, protein metabolism, RNA & DNA metabolism, amino acids  
424 and derivates, co-factors, vitamins, prosthetic groups and pigments, cell wall and capsule,  
425 fatty acids, lipids and isoprenoids, nucleotides and nucleosides, membrane transport,  
426 virulence, disease and defence, phages, prophages, transposable elements and plasmids, and  
427 regulation and signaling. Obviously, all these subsystems are necessary for the normal  
428 functional activities of the cell, except prophages, transposable elements and plasmids, and  
429 virulence, disease, and defence. Hence, most of the metabolic activities of the sputum  
430 microbiota were focused on maintaining cellular life.

431 Other studies characterising microbial communities in termite mound soils<sup>33</sup>, grassland soils  
432 <sup>34</sup>, and water reservoirs <sup>35</sup>, also found a similar composition and abundance in the microbial  
433 communities, confirming that these processes are basic to cellular life irrespective of the  
434 ecological niche. It's interesting that dormancy and sporulation structures were reduced to the  
435 basic minimum on day 1 and rose on day 7, limiting the possibility that antibiotic exposure  
436 could have increased dormancy and sporulation among the microbiota. Sharma et al. (2017)

437 observed a downregulation of MTB genes involved in ATP synthesis, aerobic respiration,  
438 translational and section machinery, etc. whilst there was no differential expression in  
439 dormancy genes (*dosRS*), suggestive of a low energy, low metabolism, and low replication  
440 state in the sputum <sup>36</sup>.

441 The  $\alpha$ -diversities show that each patient had a unique microbiome with different microbiota  
442 composition and metabolic/functional subsystems that reacted quite similarly to antibiotics  
443 (Fig. 2C & 7). The changing within-host  $\alpha$ -diversities show that antibiotics affect the  
444 microbial diversity (Fig. 2C). This is further corroborated by the inter-sample diversity within  
445 and between hosts (Fig. 2D). In particular, samples from patients 107 and 108 were very  
446 diverse from each other as well as from other samples. In all patients, changes between  
447 baseline and days 1 and 2 samples were substantial (Fig. 2D-E), representing the significant  
448 shift in diversity from baseline to days 1 and 2 after antibiotic treatment. A change in  $\alpha$ -  
449 diversity was also noticed recently in MTB+ patients BAL microbiome <sup>29</sup>. Notably, some  
450 authors have observed little or no differences in sputum microbiome diversity between TB  
451 and non-TB patients from non-Africa settings <sup>17,28</sup>. Specifically, the sampling points, 16s  
452 rRNA and pyrosequencing used were different from that used herein. Hu et al. (2020) argue  
453 that 16s rRNA-based analysis of TB-microbiome provides lower resolution than whole-  
454 genome shot-gun metagenomics <sup>29</sup>.

455 The sputum microbiota was dominated by bacteria, followed by fungi and a few parasites,  
456 viruses, and archaea. Firmicutes was the most abundant phylum among bacteria, followed by  
457 Actinobacteria and Proteobacteria. Similar microbiota compositions, albeit with little shifts in  
458 relative abundance, have been reported in other studies using 16s rRNA or shot-gun  
459 metagenomics on either sputum or BAL from TB patients <sup>15-17,25-29,32,36-41</sup>. Compared to the  
460 dysbiosis in all the microbiota (Fig. 2), the bacterial dysbiosis was most pronounced, with a  
461 substantial drop in abundance being observed on day 1 (Fig. 3). Streptococcus was the most

462 dominant genera in Firmicutes (Fig. 4)<sup>28,32,39,40</sup>, whose abundance was also affected by the  
463 antibiotic-mediated dysbiosis. In patient 105, *Leuconostoc* replaced *Streptococcus* as the  
464 most dominant genera on days 1 and 2. In patient 104, *Gemella*, *Clostridium*,  
465 *Staphylococcus*, *Solobacterium*, and *Erysipelotrichaceae* increased on day 1. *Coprobacillus*  
466 increased in abundance in 108D1 and 108D2. Similar patterns were observed in almost all  
467 samples, in which different genera emerged after a reduction in *Streptococcus* abundance  
468 (Fig. 4A).

469 Unlike Firmicutes, no single genera dominated the phylum Proteobacteria, albeit  
470 *Pseudomonas* was common in many samples (Fig. 4B)<sup>16,29,39</sup>. Specifically, baseline and day  
471 7 samples were dominated by *Pseudomonas*, suggesting that *Pseudomonas* was affected by  
472 the antibiotics, but grew back on day 7. *Neisseria* was very common in 104D0, but virtually  
473 absent in subsequent days, which also suggest that it was affected by the antibiotics. There  
474 was a notable rise in *Achromobacter* in 107D1, but it diminished again on 107D1-D7, where  
475 it was replaced by *Pseudomonas*, *Klebsiella*, and *Proteus*. These dynamics only confirm that  
476 susceptible genera were giving way to more tolerant, persistent, and resistant Proteobacterial  
477 genera.

478 The phylum Actinobacteria was dominated by *Mycobacterium*, *Atopobium*, *Actinomyces*,  
479 and *Rothia*, which has been found by Hong et al. (2018) to be always co-occurring with MTB  
480<sup>15,16,29</sup>. Unlike the phyla Firmicutes and Proteobacteria, the effect of the antibiotics on  
481 Actinobacteria were more drastic. This is not surprising as *Mycobacterium*, which these  
482 antibiotics mainly target, are found within this phylum (Fig. 4C). Moreover, compared to the  
483 other phyla, the members of this phyla did not grow back on day 7; except 108D7. Thus, anti-  
484 mycobacterial drugs were more effective against Actinobacteria than other phyla (Fig. 4).

485 Other bacterial phyla, including Aquificae, Bacteroidetes, Fusobacteria, Fibrobacteres,  
486 Chlorflexi, Cyanobacteria, Deinococcus-Thermus, Nitrospirae, Planctomycetes, Spirochaetes,  
487 Synergistetes, Tenericutes, and Verrucomicrobia were also found in the sputum  
488 microbiota<sup>28,29,32,39</sup>. Among these phyla, the commonest were Bacteroidetes (Bacteroides,  
489 Prevotella), Fusobacteria (Fusobacterium), Synergistetes, Spirochaetes (Treponema),  
490 Tenericutes (Candidatus phytolasmata), and Cyanobacteria. These phyla were  
491 also affected by the antibiotics as their abundance and diversity dropped after baseline and  
492 rose on day 7. However, in patients 107 and 108, these phyla increased in abundance on days  
493 1 and/or 2 than on day 7, with shifts in genera diversity/composition, suggesting the  
494 proliferation of resistant and/or persistent genera (Fig. 5).

495 An example of the MinION's ability to identify other potentially pathogenic genera is shown  
496 in Fig. 5 where genera such as Streptococcus (Fig. 5A), Mycobacterium (Fig. 5B),  
497 Clostridium, Schistosoma, Neisseria, Enterococcus, and Staphylococcus (Fig. 5E-F) were  
498 detected. This makes the MinION a potential diagnostic tool that can be used to detect not  
499 only *Mycobacterium tuberculosis* using sputum samples, but also other pathogens that inhabit  
500 the oral and pharyngeal cavities. Particularly in polymicrobial or secondary infections, this  
501 tool can help clinicians identify all pathogens in the patient's sample, informing appropriate  
502 antimicrobial choices. Further, it can be used to monitor treatment in patients by measuring  
503 the abundance of any pathogen over time. In this case, the efficacy of the antimicrobial  
504 agents could be seen in the declining abundance of the various genera, including  
505 Mycobacterium. When there is a regrowth of the targeted pathogen, in this case *M.*  
506 *tuberculosis*, the clinician can see it and change the antibiotics used. Finally, the shifts in the  
507 microbiota can also inform the clinician of the extent of antibiotics-mediated dysbiosis and its  
508 potential effects on the immunity and emergence of other non-susceptible and diarrhoeagenic

509 pathogens such as *Clostridium difficile*, *Shigella*, *Escherichia coli* etc. that can complicate or  
510 prolong healing<sup>6,24</sup>.

511 There was a more significant effect of the antibiotics on parasites than on fungi and viruses  
512 (Fig. 6; Dataset 3). Interestingly, in patients 105 and 107, the identified fungi genera only  
513 grew after days 2 and 7, suggesting their proliferation after the decline in the bacterial  
514 population. Similarly, in patient 108, the fungi found in the baseline samples all diminished  
515 on days 1 and 2, only to be replaced with different fungi on day 7 whilst patients 109 and 112  
516 had different genera replacing those found in their baseline samples. These observations  
517 show that the antibiotics provided advantage to other fungal genera to outgrow others.  
518 Codonosigidae and *Cryptosporidium* seemed tolerant and more resistant to the antibiotics  
519 than the other parasites as they were able to grow on days 1 to 7 with little or no reductions  
520 and substantial increments (Fig. 6; Dataset 3). Fungi belonging to Ascomycota and  
521 Basidiomycota (Fig. S6) were detected in both sputum and oropharyngeal TB samples with  
522 similar community structures<sup>26</sup>; however the effect of antibiotics on these phyla were not  
523 described.

524 Although antibiotics have no effect on viruses, reductions were seen in the abundance of  
525 Siphoviridae, Myoviridae, and Podoviridae. This could be an indirect effect through  
526 antibiotics action on bacteria, fungi, and parasites, which could be serving as cellular hosts to  
527 the viruses, which cannot exist outside of living cells. Therefore, the reducing abundance of  
528 bacteria, fungi, and parasites could be ridding the viruses of important hosts in which they  
529 can multiply, affecting their abundance as well. This demonstrates that antibiotics-mediated  
530 microbiota dysbiosis can also affect the virome population. Hence, as the bacteria, fungi, and  
531 parasites populations increased on day 7, that of the viruses also increased in tandem (Fig. 6;  
532 Dataset 3).

533 The network analysis and ordination plots show that there is a closer interaction between  
534 bacterial genera, including *Mycobacterium*, than between non-bacterial ones. This closer  
535 association was affected by antibiotics, evincing the effect of dysbiosis on the ecology of the  
536 microbiome<sup>4,6,24</sup>. The effect of such an interaction, or its lack thereof, on the pathogenesis of  
537 *M. tuberculosis* is yet to be established, although dysbiosis has been associated with  
538 increased TB pathologies. Obviously, the beneficial effects of the microbiota and their  
539 interactions on the immune system, including their production of metabolites, indirectly  
540 affects the pathogenesis of *M. tuberculosis*<sup>4,6,24</sup>.

541 Analysis of the microbiota across the samples shows the presence of external genera that are  
542 not commonly found in or part of the core oral microbiome. Examples include  
543 *Stenotrophomonas*, *Cupriavidus*, *Sphingomonas*, *Brevibacillus*, and the anaerobe, *Lautropia*  
544<sup>24,27</sup>. Except for *Lautropia* and *Brevibacillus*, the others were found in day 1 or 7 samples.  
545 Whereas Naidoo et al. (2021) found an enrichment of *Lautropia* in sputa microbiota of  
546 treatment-naïve TB patients, this was not the case in our data<sup>24</sup>. However, these observations  
547 shows the invasion of external microbiota in the upper airway microbiome due to TB or  
548 antibiotics therapy.

549 The antibiotic resistance mechanisms and MGEs of the microbiota in the sputum samples  
550 were determined and found to be relatively few. It is noteworthy that all the recruited patients  
551 were newly diagnosed with TB and were not found to have rifampicin or multidrug resistance  
552 by GeneXpert and the line probe<sup>5,6,8,9,42</sup>. However, an analysis of the microbiota identified  
553 resistance-mediating mutations in genes that confer resistance to TB drugs such as  
554 aminoglycosides, quinolones, isoniazid, capreomycin, rifampicin, ethambutol, ethionamide,  
555 and pyrazinamide as well as to non-TB antibiotics in a few of the samples; particularly,  
556 108D0<sup>5,8,9</sup>. The absence of these mutations in subsequent samples could suggest that these  
557 mutations were not enough to withstand the effect of all four antibiotics combined. Moreover,

558 this evidence shows that the MinION can not only detect the presence of Mycobacterium but  
559 also its resistance profiles, and possibly lineage, in sputum samples, particularly when  
560 sequenced at a higher coverage. The resistance mechanisms of the other microbiota and their  
561 MGEs can also be determined to inform important clinical decisions.

562 Finally, the data suggests that age and sex had little to do with the outcome of the findings as  
563 same or similar patterns were observed in samples from different ages and sexes; findings by  
564 Wu et al. (2013) also concur<sup>39</sup>. Larger cohorts may be necessary in future studies to confirm  
565 the absence of any effect of age and/or sex on the sputum microbiota and its response to anti-  
566 tubercular therapy.

### 567 ***Conclusion***

568 ONT's MinION sequencer is a portable device that can be used to detect Mycobacterium in  
569 sputum samples of patients newly diagnosed with TB, monitor their response to treatment,  
570 detect the presence of other pathogens (polymicrobial infections) in the sputum samples,  
571 identify resistance genes and MGEs, and monitor the effect of administered antibiotics on the  
572 sputum microbiota. With the introduction of advanced flow cells and kits that can multiplex  
573 at most 96 samples (<https://store.nanoporetech.com/us/pcr-barcoding-expansion-1-96.html>),  
574 it is even cheaper and faster to detect the presence of *M. tuberculosis* and other pathogens,  
575 their resistance and virulence mechanisms as well as their MGEs in clinical samples within 6-  
576 48 hours. The presence of other pathogens that may not be targeted by routine  
577 microbiological assays, can be easily detected by the MinION, helping clinicians treat  
578 polymicrobial and idiopathic infections. The sequence lengths produced by the MinION,  
579 which ranged from 1500-4000bp, coupled with higher coverage, can enhance its sensitivity  
580 and specificity for detecting all commensals and pathogens as well as their clones/lineages.



581 The comprehensive data provided by this new technology makes it ideal for clinical  
582 microbiology laboratories to detect all pathogens with little laboratory accoutrements. We  
583 show that the oral administration of anti-tubercular chemotherapy affects the sputum  
584 microbiota by reducing their abundance and shifting their diversity from onset of treatment  
585 (day 1) until day 7, when persistent, tolerant, and resistant microbiota, including fungi, begins  
586 to grow back to replenish the microbiome. Hence, antibiotics usage after one week should be  
587 done with caution as it can result in drug-resistant infections.

588 **Funding sources:** This study was funded by (1) South African National Research Foundation  
589 Grant number UID 127338; (2) CRDFGlobal Grant number DAA9-20-66880-1.

590 **Acknowledgement:** We are grateful to the following persons for their help in this work. (1)  
591 Patient screening: Sr Mkhondo, Stanza Bopape Community Health Centre TB Clinic,  
592 Pretoria; (2) Field work and specimen collections: Ms Phindile Ntuli, Ms Sharon Olifant; (3)  
593 Donation of PrimeStore Molecular Transport Medium: Longhorn Vaccines and Diagnostics,  
594 San Antonio, TX (only if the product is mentioned in the manuscript).

595 We especially dedicate this work to the memory of Professor Nontombi Marylucy Mbelle  
596 Ph.D., who passed away in January 2021, prior to the completion and submission of this  
597 work.

598 **Transparency declaration:** The authors declare no conflict of interest and the funders had  
599 no influence or decision whatsoever in the decision to write-up and publish this work.

600 **Author contributions:** **JOS** designed and carried out all the laboratory (experimental),  
601 sequencing, bioinformatics, and statistical aspects of this work. He also wrote the article and  
602 formatted for publication. **NEM** and **SRM** assisted with the experimental sections of this  
603 work. **NMM** assisted with funding and sequencing reagents for this work. **PBF** supervised

604 this work and provided funding for it. All authors reviewed this work prior to submission for  
605 publication.

## 606 **References**

- 607 1. Kay, G. L. *et al.* Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis  
608 in Europe. *Nat. Commun.* **6**, 1–9 (2015).
- 609 2. Donoghue, H. D. Insights into ancient leprosy and tuberculosis using metagenomics. *Trends Microbiol.* **21**, 448–  
610 450 (2013).
- 611 3. Cambier, C. J., Falkow, S. & Ramakrishnan, L. Host Evasion and Exploitation Schemes of Mycobacterium  
612 tuberculosis. *Cell* **159**, 1497–1509 (2014).
- 613 4. Naidoo, C. C. *et al.* The microbiome and tuberculosis: state of the art, potential applications, and defining the  
614 clinical research agenda. *The Lancet Respiratory Medicine* **7**, 892–906 (2019).
- 615 5. Osei Sekyere, J., Reta, M. A., Maningi, N. E. & Fourie, P. B. Antibiotic resistance of Mycobacterium tuberculosis  
616 complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics.  
617 *Journal of Infection* **79**, 550–571 (2019).
- 618 6. Osei Sekyere, J., Maningi, N. E. & Fourie, P. B. Mycobacterium tuberculosis , antimicrobials, immunity, and lung–  
619 gut microbiota crosstalk: current updates and emerging advances. *Ann. N. Y. Acad. Sci.* **1467**, 21–47 (2020).
- 620 7. WHO. *Global Tuberculosis Report 2020*. Who (2020). doi:WHO/HTM/TB/2017.23
- 621 8. Maningi, N. E. *et al.* Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a  
622 Molecular Analysis of Historical Isolates. *J. Clin. Microbiol.* **56**, JCM.01214-17 (2018).
- 623 9. osei Sekyere, J., Maphalala, nontobeko, Malinga, L. A., Mbelle, nontombi M. & Maningi, nontuthuko E. A  
624 Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting  
625 Tuberculosis in Pulmonary and Extra Pulmonary Specimens. *Sci. Rep.* **9**, (2019).
- 626 10. Dickson, R. P. & Huffnagle, G. B. The Lung Microbiome: New Principles for Respiratory Bacteriology in Health  
627 and Disease. *PLoS Pathog.* **11**, 1–5 (2015).
- 628 11. Shukla, S. D., Budden, K. F., Neal, R. & Hansbro, P. M. Microbiome effects on immunity, health and disease in the  
629 lung. *Clin. Transl. Immunol.* **6**, e133 (2017).
- 630 12. O’Dwyer, D. N., Dickson, R. P. & Moore, B. B. The Lung Microbiome, Immunity and the Pathogenesis of Chronic  
631 Lung Disease. *J Immunol* **196**, 87–92 (2016).
- 632 13. Hauptmann, M. & Schaible, U. E. Linking microbiota and respiratory disease. *FEBS Lett.* **590**, 3721–3738 (2016).
- 633 14. Evsytina, Y., Komkova, I., Zolnikova, O., Tkachenko, P. & Ivashkin, V. Lung microbiome in healthy and diseased  
634 individuals. *World J. Respirol.* **7**, 39–47 (2017).
- 635 15. Hong, B. young, Paulson, J. N., Stine, O. C., Weinstock, G. M. & Cervantes, J. L. Meta-analysis of the lung  
636 microbiota in pulmonary tuberculosis. *Tuberculosis* **109**, 102–108 (2018).
- 637 16. Hu, Y. *et al.* Distinct lung microbial community states in patients with pulmonary tuberculosis. *Sci. China. Life Sci.*  
638 **63**, 1522–1533 (2020).
- 639 17. Sala, C. *et al.* Multicenter analysis of sputum microbiota in tuberculosis patients. *PLoS One* **15**, e0240250 (2020).
- 640 18. Doughty, E. L., Sergeant, M. J., Adetifa, I., Antonio, M. & Pallen, M. J. Culture-independent detection and  
641 characterisation of Mycobacterium tuberculosis and M. africanum in sputum samples using shotgun metagenomics  
642 on a benchtop sequencer. *PeerJ* **2**, 1–18 (2014).
- 643 19. Zhang, Y., Lun, C. Y. & Tsui, S. K. W. Metagenomics: A new way to illustrate the crosstalk between infectious  
644 diseases and host microbiome. *International Journal of Molecular Sciences* **16**, 26263–26279 (2015).
- 645 20. Martinez, X. *et al.* MetaTrans: An open-source pipeline for metatranscriptomics. *Sci. Rep.* **6**, 1–12 (2016).
- 646 21. Bashardes, S., Zilberman-schapira, G. & Elinav, E. Use of Metatranscriptomics in Microbiome Research.  
647 *Bioinform. Biol. Insights* **10**, 19–25 (2016).
- 648 22. Lee, R. S. & Behr, M. A. The implications of whole-genome sequencing in the control of tuberculosis. *Ther. Adv.*

- 649 *Infect. Dis.* **3**, 47–62 (2016).
- 650 23. Witney, A. A. *et al.* Clinical use of whole genome sequencing for Mycobacterium tuberculosis. *BMC Med.* **14**, 46  
651 (2016).
- 652 24. Naidoo, C. C. *et al.* Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary  
653 tuberculosis. *EBioMedicine* **67**, 103374 (2021).
- 654 25. Eshetie, S. & Van Soolingen, D. The respiratory microbiota: New insights into pulmonary tuberculosis. *BMC Infect.*  
655 *Dis.* **19**, 1–7 (2019).
- 656 26. Botero, L. E. *et al.* Respiratory tract clinical sample selection for microbiota analysis in patients with pulmonary  
657 tuberculosis. *Microbiome* **2**, 29 (2014).
- 658 27. Cui, Z. *et al.* Complex sputum microbial composition in patients with pulmonary tuberculosis. *BMC Microbiol.* **12**,  
659 276 (2012).
- 660 28. Cheung, M. K. *et al.* Sputum Microbiota in Tuberculosis as Revealed by 16S rRNA Pyrosequencing. *PLoS One* **8**,  
661 e54574 (2013).
- 662 29. Hu, Y. *et al.* Metagenomic analysis of the lung microbiome in pulmonary tuberculosis - a pilot study. *Emerg.*  
663 *Microbes Infect.* **9**, 1444–1452 (2020).
- 664 30. Keegan, K. P., Glass, E. M. & Meyer, F. MG-RAST, a metagenomics service for analysis of microbial community  
665 structure and function. in *Methods in Molecular Biology* **1399**, 207–233 (Humana Press Inc., 2016).
- 666 31. McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of  
667 Microbiome Census Data. *PLoS One* **8**, e61217 (2013).
- 668 32. Kateete, D. P. *et al.* Sputum microbiota profiles of treatment-naïve TB patients in Uganda before and during first-  
669 line therapy. *bioRxiv* (2020). doi:10.1101/2020.04.24.20078246
- 670 33. Enagbonma, B. J., Amoo, A. E. & Babalola, O. O. Deciphering the microbiota data from termite mound soil in  
671 South Africa using shotgun metagenomics. *Data Br.* **28**, (2020).
- 672 34. Delmont, T. O. *et al.* Structure, fluctuation and magnitude of a natural grassland soil metagenome. *ISME J.* **6**,  
673 1677–1687 (2012).
- 674 35. Soriano, B. M., Del Valle-Perez, L. M., Morales-Vale, L. & Rios-Velazquez, C. Datasets generated by shotgun  
675 sequencing of metagenomic libraries of the guajataca water reservoir. *Data Br.* **21**, 2531–2535 (2018).
- 676 36. Sharma, S. *et al.* Transcriptome analysis of mycobacteria in sputum samples of pulmonary tuberculosis patients.  
677 *PLoS One* **12**, 1–16 (2017).
- 678 37. Maiga, M. *et al.* Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for  
679 Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali. *J. Breath Res.* **10**, 36012 (2016).
- 680 38. Vázquez-Pérez, J. A. *et al.* Alveolar microbiota profile in patients with human pulmonary tuberculosis and  
681 interstitial pneumonia. *Microb. Pathog.* **139**, 103851 (2020).
- 682 39. Wu, J. *et al.* Sputum microbiota associated with new, recurrent and treatment failure tuberculosis. *PLoS One* **8**,  
683 e83445 (2013).
- 684 40. Krishna, P., Jain, A. & Bisen, P. S. Microbiome diversity in the sputum of patients with pulmonary tuberculosis.  
685 *Eur. J. Clin. Microbiol. Infect. Dis.* **35**, 1205–1210 (2016).
- 686 41. Lin, D. *et al.* Sputum microbiota as a potential diagnostic marker for multidrug-resistant tuberculosis. *Int. J. Med.*  
687 *Sci.* **18**, 1935–1945 (2021).
- 688 42. Osei Sekyere, J. & Asante, J. Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in  
689 the era of genomics. *Future Microbiol.* **13**, 241–262 (2018).

690

691

692

693 **Figure 1.** Demographic information and sputum sampling of recruited patients. The patients  
694 were aged between 23 and 55 years, with a median age of 38 years and average age of 37.41  
695 years (**A**). Six of the patients were females whilst 15 were males, with the females and males  
696 having a respective mean age of 30.60 and 40.25 years (**B**). Sputum samples collected at  
697 baseline, day 1, day 2, and day 7 were obtained from 7 patients whilst three patients provided  
698 samples at baseline, day 1, and day 2, and one patient provided only baseline and day 7  
699 sputum samples (**C**). Only nine of the 11 sequenced reads qualified for inclusion in  
700 downstream analysis owing to their higher coverage (>10X) (**D**).

701 **Figure 2. Count and abundance of genera OTU per sample, and alpha and beta**  
702 **diversities.** The total abundance of genera OTUs across all samples shows that 104D0 and  
703 108D0 had the highest OTU abundance. Only a few genera had significant (t-test) abundance  
704 variation across each sample: 104D1 (p: 0.031), 105D2 (p: 0.2376), 107D2 (p: 0.007), 108D2  
705 (p: 0.0114), 109D2 (p: 0.0178) (**A**). Wilcoxon's test found all genera abundance to be  
706 significant (p: <0.0001), but they were insignificant by t-test; one- & two-way ANOVA were  
707 both significant. The count of all genera (OTUs) per sample shows sample 108D0 had the  
708 highest number of genera; count per genera was statistically significant (p: <0.0001) (**B**).  
709 Alpha-diversity of each sample is shown in **C** and they were all significant (p: <0.0001). The  
710  $\beta$ -diversities between samples of the same patient are shown in **D**, with the variations  
711 between  $\beta$ -diversities varying per patient (p: <0.0001).  $\beta$ -diversity between baseline (S1) and  
712 day 1 (S2) is shown as blue bars, between baseline and day 2 (S3) is shown as orange bars,  
713 between baseline and day 7 (S4) is shown as grey bars, between days 1 (S2) and 2 (S3) is  
714 shown as yellow bars, between days 1 and 7 is shown as light blue bars, and between days 2  
715 and 7 are shown as green bars. The  $\beta$ -diversity variations between samples collected at the  
716 same time point (days 0, 1, 2, and 7) from different patients is shown in **E** (p: 0.0821;  
717 <0.0001). S1, S2, S3, and S4 represent days 0 (baseline), 1, 2, and 7 respectively. The  $\beta$ -

718 diversity variation between samples collected at the same time points, but from different  
719 patients, are shown as coloured bars: blue (baseline), orange (day 1), grey (day 2) and yellow  
720 (day 7).

721 **Figure 3. Total abundance of taxonomic Kingdoms per sample.** Bacteria was most  
722 dominant across all samples except in 107D2, 109D1, 109D2, where Fungi was most  
723 dominant. Parasites were also found in substantial proportions in 104D1, 105D2, 107D7,  
724 108D1, 108D2, 109D1, 109D2, and 112D2, but viruses and archaea were very minor in  
725 abundance in all the samples. Wilcoxon's test showed significance ( $p < 0.0001$ ) for all  
726 kingdoms and 2-Way ANOVA was significant for the samples (**A**). Among almost all the  
727 samples, the bacterial phylum Firmicutes was the most dominant, except in 105D2, 107D2,  
728 108D1, and 112D2 where it was almost absent. Actinobacteria was the next dominant  
729 phylum, with Proteobacteria, Bacteroidetes and the other phyla occupying a relatively small  
730 portion of the microbiota. A reduction in bacterial phyla abundance was seen after the  
731 baseline until on day 7, when a rise in abundance was observed again in all the samples (**B**).

732 **Figure 4. Abundance and diversity of OTUs in Firmicutes, Proteobacteria,**  
733 **Actinobacteria, Bacteroides and other bacterial orders in sputum samples.** A u-shaped  
734 pattern was observed among genera in the various phyla: they reduced in abundance after day  
735 0 and rose gradually from day 2 to day 7. The diversities reduced or increased depending on  
736 the patient. The abundance and diversity of genera found in the phylum Firmicutes is shown  
737 in **A**; Streptococcus was the commonest genus and reduced after baseline but rose gradually  
738 from day 2 unto day 7. This u-shaped pattern was observed in other genera under Firmicutes.  
739 Abundance and diversity of genera under Proteobacteria are shown in **B**, in which  
740 Pseudomonas was the most abundant. Among Actinobacteria (**C**), Mycobacterium was  
741 common, but also reduced drastically after the baseline and hardly rose again, making it the  
742 genera most affected by the antibiotics. Bacteroidetes, Cyanobacteria, Tenericutes and other

743 Phyla with relatively little abundance are shown in **D**. Within these phyla, the u-shaped  
744 pattern was also observed from baseline to day 7, with days 1 and 2 having lower  
745 abundances.

746 **Figure 5. Abundance of selected genera in all samples across different sampling-time**  
747 **points.** The abundance of Streptococcus (**A**), Mycobacterium (**B**), and different sets of  
748 selected genera (**C, D, E, and F**) across different sampling-time points (baseline, day 1, day  
749 2, and day 7) showed a reduction in abundance after baseline on days 1 and 2, and a rise on  
750 day 7. However, Mycobacterium declined after the baseline and continued declining  
751 afterwards. The variations in abundance over sampling time was significant for Streptococcus  
752 (p: 0.0078) Granulicatella (p: 0.0432), Clostridium, Lactobacillus (p: 0.0272),  
753 Bifidobacterium (p: 0.0071), Bacillus (0.0141) etc. by one-sample t-test, and was significant  
754 for almost all the selected genera, including Mycobacterium (p: <0.0001). One-/two-way  
755 ANOVA matching of the genera to their abundance were significant (Dataset 3).

756 **Figure 6. Abundance of archaea, parasite, fungi, and viral OTUs per sample.** The  
757 abundance of archaeal OTUs is shown in **A**, where only 108D0 had 4 archaeal genera; Two-  
758 way ANOVA was significant for only the row factor. Both Wilcoxon's and one-sample t-  
759 tests were insignificant. Abundance of parasites per sample is shown in **B**; parasites were  
760 found in all samples with non-consistent variations in abundance across different sampling-  
761 time points per patient. Two-way ANOVA column factor was significant. Schistosoma  
762 (p:0.0014), Moniezia (p:0.0187), Drosophila (p:0.0406), Plasmodium (p:0.0404), &  
763 Monosiga (p:0.0256) were significant by one-sample & Wilcoxon's tests; Noniella (p:0.0005)  
764 & Codonosigidae (p:<0.0001) were only significant with Wilcoxon's test. The abundance and  
765 variations of 51 fungal OTUs across different sampling-times per patient is shown in **C**; 2-  
766 Way ANOVA of fungi genera with abundance was insignificant. Also, none of the  
767 abundance variations in any of the fungal genera were significant except Saccharomyces

768 (p:0.0078) & Penicillium (p:0.0078). Siphoviridae, Podoviridae, Myoviridae, Retroviridae,  
769 Anelloviridae, T4-like, Muromegalovirus, Caudovirales, and Lymphocryptovirus viruses  
770 were the viruses found in mainly baseline and day 7 samples, with 107D2 and 111D1 being  
771 the only samples from days 2 and 1, respectively (**D**). Although the presence of viruses in the  
772 samples were significant (2-Way ANOVA), none of the variations in abundance for every  
773 virus OTU was significant.

774 **Figure 7. Functional component subsystem distribution per sample.** The functional  
775 composition of each sample is shown in **A**, where clustering-based subsystems,  
776 carbohydrates, protein metabolism etc., dominated the samples. The samples with the most  
777 abundant functional subsystems components were mainly baseline and day 7 samples such as  
778 104D0, 108D0, 108D7, 111D7, 112D0, 109D7, 107D7, and 107D0 (**B**). A sampling time-  
779 point grouping shows that baseline and day 7 samples had the most functional components  
780 whilst days 1 and 2 samples had lower functional components (**C**). U-shaped patterns were  
781 observed across the sampling points, with abundance of functional components reducing  
782 from baseline to days 1 and 2, and increasing on day 7 (**D**). Functional subsystems  
783 components with the most substantial proportion in all the samples shows that clustering-  
784 based subsystems, carbohydrates, protein metabolism, RNA metabolism, amino acids and  
785 derivatives, and DNA metabolism were common subsystems. These varied across the samples  
786 at different sampling points: baseline, day 1, day 2, and day 7 (**E**). The variations in  
787 abundance for the functional components of each sample was statistically significant; two-  
788 way ANOVA was significant.

789 **Figure 8. Nonmetric multidimensional scaling (NMDS) and ordination plots.** The  
790 microbiota were closely related to each other at baseline, but became less related/connected at  
791 days 1 and 2; the networks between the microbiota increased at day7. The network analysis  
792 of the microbiota between baseline and day 2 is shown in **A** and **B** respectively. The

793 ordination plots showing the spatial relationship between the microbiota are shown in **C** and  
794 **D** respectively.

795 **Dataset 1.** Patient demographics, sputum sampling, and sputum characteristics

796 **Dataset 2.** Operational taxonomic units (OTU) abundance per sputum sample, taxonomy,  
797 metadata, resistance mechanisms and mobile genetic elements in each sputum sample.

798 **Dataset 3.** Statistical analyses of microbiome OTU data per sample.

799 **Figure S1. Total OTU abundance of the various genera across all samples.** The total  
800 abundance of each OTU genera across all samples are categorised into four: above 1000 (**A**),  
801 between 1000-100 (**B**), between 100-10 (**C**), and below 10 (**D**). Most genera were below 10  
802 and a few were above 1000.

803 **Figure S2. Chao1 and Shannon alpha diversities of samples according to daily**  
804 **collections and OTU genera categorisation.** The Chao1 and Shannon indices differed from  
805 each other for the same sample and patient.

806 **Figure S3. Abundance of each taxonomic rank, from kingdom to genus, in each sample.**  
807 A detailed breakdown of each kingdom, phylum, class, order, family, and genus in each  
808 sample across all time points and in only baseline, day 1, 2, and 7 samples are shown in i to  
809 xxx.

810 **Figure S4. Abundance of bacterial OTUs per taxonomic rank and sampling-time point**  
811 **per sample.** Common bacterial genera included Streptococci, Mycobacterium, Veillonella,  
812 and Pseudomonas. Abundance of each OTU per taxonomic rank and sampling time-points  
813 shows antibiotic-mediated variations from baseline to day 7.

814 **Figure S5. Abundance of parasite OTUs per taxonomic rank and sampling-time point**  
815 **per sample.**



816 **Figure S6. Abundance of fungi OTUs per taxonomic rank and sampling-time point per**  
817 **sample.**

818 **Figure S7. Abundance of viral OTUs per taxonomic rank and sampling-time point per**  
819 **sample.**

820 **Figure S8. Functional components and subsystems of the various samples.** The functional  
821 components and subsystems shifted in proportion per sample for the different sampling  
822 points.

823 **Figure S9. Network analysis showing the spatial interactions and networking of the**  
824 **various microbial components in the sputum microbiota.**

825 **Figure S10. Non-metric multidimensional scaling (NMDS) of the various OTUs showing**  
826 **their ordination plots and spatial orientation per kingdom.**

827

828





829




830



831

832





833































**A****Abundance of Archaea per sample****B****Abundance of Parasites per sample****C****Relative abundance of Fungi per sample****D****Abundance of viruses per sample**







**A****B**